Form 4: Ligand Pharmaceuticals CEO Todd C. Davis Reports Stock Transactions
SEC Form 4 Filing
CEO Todd C. Davis reports acquisition and disposal of Ligand Pharmaceuticals stock due to vesting of performance stock units and tax liabilities.
Summary
- On February 14, 2025, Todd C. Davis, CEO of Ligand Pharmaceuticals, acquired 20,784 shares of common stock upon the vesting of performance stock units (PSUs) at a price of $0.0.
- On the same day, 6,966 shares were disposed of to cover tax liabilities related to the PSU settlement at a price of $120 per share.
- On February 15, 2025, additional shares were disposed of to cover tax liabilities related to the settlement of restricted stock units (RSUs): 2,231 shares and 4,255 shares, both at a price of $120 per share.
- Following these transactions, Davis directly owns 130,342 shares of Ligand Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions related to executive compensation. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and are closely monitored by investors for insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's holdings, but the overall impact is likely minimal as these are routine transactions.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Acquisition of 20,784 shares of common stock upon vesting of performance stock units (PSUs) and disposal of 6,966 shares for tax liabilities. |
| 02/15/2025 | Disposal of 2,231 and 4,255 shares to cover tax liabilities related to the settlement of restricted stock units (RSUs). |
| 02/19/2025 | Date of signature for the Form 4 filing. |
Keywords
Ligand Pharmaceuticals, LGND, Todd C. Davis, CEO, Form 4, Stock Transactions, Performance Stock Units, Restricted Stock Units, Beneficial Ownership, Tax Liabilities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.